Romatoid Artrit Hastalarında Tofasitinib, Tocilizumab veya Diğer Biyolojik Tedavilerin Gastrointestinal Perforasyon Riskleri
Arthritis Rheumatol. 2016 May 17. DOI 10.1002/art.39761 [Epub ahead of print]
Historically, patients with RA have suffered with upper tract gastrointestinal perforation (GIPs), associated with NSAID use. More recently, the IL-6 receptor antagonist tocilizumab (TCZ) has been associated with lower tract GIPs. Janus kinase (JAK) inhibitors, including tofacitinib (TOF), with some downstream effects on IL-6 signalling, also have potential for an increased risk of GIPs.There is limited real-world evidence and almost no comparative evidence on the risk for GIP associated with TC...